You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed or Refractory Acute Promyelocytic Leukemia

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

APL Trial in Shanghai (Chidamide+venetoclax)

Active, not recruiting
  • APL
  • Shanghai, Shanghai, China
    Jiong HU
May 30, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia With Failed Remission
  • São Paulo, SP, Brazil
    Instituto do Cancer do Estado de Sao Paulo
Sep 12, 2023

AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed

Recruiting
  • AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
  • MRD-triggered arm
  • Prophylactic Arm
  • Heidelberg, BW, Germany
    University Hospital Heidelberg Med5
Jan 4, 2021

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)

Recruiting
  • Acute Myeloid Leukemia
  • Beijing, Beijing, China
    Peking University People's Hospital
Jun 23, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • B7-H3 target, CAR gene modified gdT cell injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital， Zhejiang University School of Med
Feb 15, 2023

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • (no location specified)
Nov 9, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia
  • Taiyuan, Shanxi, China
    Tao Wang
Feb 9, 2023

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

PET-CT Imaging in Relapsed/Refractory Acute Leukemias

Not yet recruiting
  • B Cell
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 4, 2023

    B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

    Not yet recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • (no location specified)
    Oct 10, 2023

    T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

    Not yet recruiting
    • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    • CD7-CART01
    • (no location specified)
    Sep 26, 2023

    Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)

    Not yet recruiting
    • Relapsed/Refractory AML
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Mar 28, 2023

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • gdT cell injection targeting B7-H3 chimeric antigen receptor
    • Hefei, Anhui, China
      PersonGen Anke Cellular Therapeutice Co., Ltd.
    Jan 31, 2023

    Acute Myeloid Leukemia (Relapsed/Refractory) Trial in Suzhou (Selinexor, Chidamide)

    Recruiting
    • Acute Myeloid Leukemia (Relapsed/Refractory)
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jul 16, 2023

    Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL Trial in Dresden (observational)

    Recruiting
    • Newly-diagnosed APL (de Novo or Therapy-related)
    • Relapsed APL
    • observational
    • Dresden, Germany
      Prof. Dr. U. Platzbecker
    Aug 10, 2022

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
    • Best-Available Therapy(BAT) Regimen
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Oct 10, 2023

    Acute Promyelocytic Leukemia, Induction Therapy, Oral Trial in Beijing (Etoposide, Daunorubicin)

    Recruiting
    • Acute Promyelocytic Leukemia
    • +2 more
    • Beijing, Beijing, China
      Peking University Institute of Hematology
    Apr 26, 2023

    B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

    Not yet recruiting
    • B Precursor Acute Lymphoblastic Leukemia
    • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
    • (no location specified)
    Sep 25, 2023

    Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse Trial in Miami (Bomedemstat,

    Recruiting
    • Acute Myeloid Leukemia
    • +2 more
    • Miami, Florida
      University of Miami
    Dec 22, 2022

    Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)

    Recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndromes
    • Duarte, California
    • +3 more
    Nov 21, 2023

    Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • High-Risk and Very High-Risk Myelodysplastic Syndromes
    • (no location specified)
    Jul 25, 2023